CNXC vs. ARCT

In the year-to-date period, CNXC achieves a 30.29% return, which is significantly higher than ARCT's -31.70% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Concentrix Corporation (CNXC) and Arcturus Therapeutics Holdings Inc. (ARCT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current CNXC Sharpe Ratio is -0.08, which is higher than the ARCT Sharpe Ratio of -0.74. The chart below compares the historical Sharpe Ratios of CNXC and ARCT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

CNXC's dividend yield for the trailing twelve months is around 2.34%, while ARCT has not paid dividends to shareholders.

The maximum CNXC drawdown since its inception was -81.19%, smaller than the maximum ARCT drawdown of -92.79%. Use the drawdown chart below to compare losses from any high point for CNXC and ARCT. For additional features, visit the drawdowns tool.

The current volatility for Concentrix Corporation (CNXC) is 10.26%, while Arcturus Therapeutics Holdings Inc. (ARCT) has a volatility of 19.06%. This indicates that CNXC experiences smaller price fluctuations and is considered to be less risky than ARCT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Concentrix Corporation and Arcturus Therapeutics Holdings Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.